Nova In Silico was established in 2024 following the acquisition of assets from Novadiscovery. As a pioneering company in the field of in silico clinical trials, Nova In Silico leverages advanced computational models to revolutionize the design and execution of clinical trials by digitally simulating the efficacy on hundreds of thousands of virtual patients, each with its own unique physiological makeup.
Nova In Silico
